Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYZINE HYDROCHLORIDE versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYZINE HYDROCHLORIDE versus XYZAL.
HYDROXYZINE HYDROCHLORIDE vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine hydrochloride is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors. It also possesses anticholinergic, antiemetic, and sedative properties. Its mechanism involves binding to H1 receptors in the gastrointestinal tract, uterus, blood vessels, and bronchial muscles, thereby inhibiting histamine-mediated effects.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
25-100 mg orally or intramuscularly 3-4 times daily; maximum 600 mg/day.
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in adults. In elderly or hepatic impairment, may be prolonged. Clinical context: Achieves steady-state after ~4-5 days; detectable for >72 hours after cessation.
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Primarily hepatic metabolism via CYP3A4 and CYP3A5; <1% excreted unchanged in urine. Renal elimination of metabolites (approx. 50-60% of total clearance), with minor fecal excretion (<10%).
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category A/B
Category C
Antihistamine
Antihistamine